"A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy." by Anthony R. Mato

Selected Works of John M. Pagel, MD, PhD

Article

A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy.

Journal of Clinical Oncology (2018)

Anthony R. Mato, Memorial Sloan Kettering Cancer Center
Stephen J. Schuster, Abramson Cancer Center, Philadelphia, PA;
Nicole Lamanna, Columbia University Medical Center
Ian Flinn, Sarah Cannon Research Institute
Jacqueline Claudia Barrientos, Northwell Health/CLL Research and Treatment Program, New Hyde Park, NY;
Suman Kambhampati, Sarah Cannon Research Institute
Bruce D. Cheson, Georgetown University
Paul M. Barr, University of Rochester Medical Center
John M. Pagel, Swedish Cancer Institute, Seattle, WA;
James Andrew Reeves, Sarah Cannon Research Institute
Frederick Lansigan, Dartmouth–Hitchcock Medical Center
Jeffrey J. Pu, Penn State Cancer Institute
Alan P. Skarbnik, City of Hope National Medical Center
Gustavo A. Fonseca, Sarah Cannon Research Institute
Colleen Dorsey, Memorial Sloan Kettering Cancer Center
Eline Luning Prak, Hospital of the University of Pennsylvania
Dana Paskalis, TG Therapeutics, Inc., New York, NY;
Peter Sportelli, TG Therapeutics, Inc., New York, NY;
Hari P. Miskin, TG Therapeutics, Inc., New York, NY;
Danielle M. Brander, Duke University

Link

Disciplines

Publication Date

May 20, 2018

DOI

10.1200/jco.2018.36.15_suppl.7530

Citation Information

Anthony R. Mato, Stephen J. Schuster, Nicole Lamanna, Ian Flinn, et al.. "A phase 2 study to assess the safety and efficacy of umbralisib (TGR-1202) in pts with CLL who are intolerant to prior BTK or PI3Kδ inhibitor therapy." Journal of Clinical Oncology Vol. 36 (2018) p. 7530 - 7530
Available at: http://works.bepress.com/john-pagel/302/